A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
This study will be a randomized 3-treatment, cross-over study to evaluate the bioavailability of lapatinib administered after a high or low-fat meal.
Neoplasms, Breast
DRUG: Lapatinib
Protocol specified pharmacokinetic parameters, 3 weeks
Safety and tolerability as assessed by evaluation of adverse events (AEs), changes in laboratory values, and vital signs, 3 weeks
This study will be a randomized 3-treatment, cross-over study to evaluate the bioavailability of lapatinib administered after a high or low-fat meal.